An evaluation of the sensitivity of the Ames assay to discern low-level mutagenic impurities.

Low level impurities often reside in active pharmaceutical ingredients (API). Some of these impurities are potentially genotoxic since reactive intermediates are used in the synthetic route for the production of API. Routine mutagenicity testing is conducted in support of clinical trials with the intent to identify genotoxic hazards associated with API. Depending on the amount of impurity present in the API tested, the potency of the impurities and the relative sensitivity of the Ames assay, it is possible that mutagenicity associated with the presence of genotoxic impurities could also be detected while testing API. Therefore, we evaluated published data and generated new information to understand the sensitivity of the Ames assay. Based on a literature survey of approximately 450 mutagens, it was estimated that 85% of mutagens are detected at concentrations of 250 microg/plate or less. Based on this estimate, most mutagens should be detected in an Ames assay testing API concentrations up to 5000 microg/plate if present at a 5% or greater concentration. Data from experiments where several direct and indirect-acting mutagens were spiked into representative API further support the literature-based evaluation. Some limitations of this approach, including toxicity of API and competing metabolism are discussed.

[1]  Lutz Müller,et al.  A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. , 2006, Regulatory toxicology and pharmacology : RTP.

[2]  M. Eichelbaum,et al.  Identification of P450 enzymes involved in metabolism of verapamil in humans , 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.

[3]  J E Ridings,et al.  Computer prediction of possible toxic action from chemical structure: an update on the DEREK system. , 1996, Toxicology.

[4]  T Satoh,et al.  Advantage of the use of human liver S9 in the Ames test. , 1999, Mutation research.

[5]  E. Zeiger,et al.  Salmonella mutagenicity test results for 250 chemicals. , 1983, Environmental mutagenesis.

[6]  C. Bonfils,et al.  Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[7]  T. Satoh,et al.  Use of human liver S9 in the Ames test: assay of three procarcinogens using human S9 derived from multiple donors. , 2003, Regulatory toxicology and pharmacology : RTP.

[8]  R. Riley,et al.  Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[9]  R. Riggin,et al.  Characterization of impurities in commercial lots of sodium saccharin produced by the Sherwin-Williams process. II. Mutagenicity. , 1983, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[10]  G. Kondos,et al.  Near-total reduction in verapamil bioavailability by rifampin. Electrocardiographic correlates. , 1988, Chest.

[11]  E. G. Lovering,et al.  Determination of hydrazine in pharmaceuticals III: hydralazine and isoniazid using GLC. , 1983, Journal of pharmaceutical sciences.

[12]  B. Ames,et al.  Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Wold,et al.  Chemical purity and mutagenicity: case study of a drug in development. , 1992, Mutation research.

[14]  N Flamand,et al.  Mini mutagenicity test: a miniaturized version of the Ames test used in a prescreening assay for point mutagenesis assessment. , 2001, Toxicology in vitro : an international journal published in association with BIBRA.

[15]  J. Topinka,et al.  Bioassay-directed chemical analysis and detection of mutagenicity in ambient air of the coke oven. , 1999, Mutation research.

[16]  Detection of oxidative mutagens in an urban air-particulate extract: a preliminary study. , 1992, Mutation research.

[17]  P N Judson,et al.  Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. , 1999, SAR and QSAR in environmental research.

[18]  B. Ames,et al.  Revised methods for the Salmonella mutagenicity test. , 1983, Mutation research.

[19]  D J Judah,et al.  Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B1 metabolism in human liver. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[20]  H. Utsumi,et al.  Mutagenicity Characteristics of 255 Environmental Chemicals , 2002 .

[21]  J. Epler,et al.  Short-Term Bioassay of Complex Organic Mixtures: Part I, Chemistry , 1978 .

[22]  Andreas Hartmann,et al.  Towards the creation of an international toxicology information centre. , 2005, Toxicology.

[23]  M. Murray,et al.  Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. , 1997, The Journal of pharmacology and experimental therapeutics.

[24]  E. Zeiger,et al.  Salmonella mutagenicity tests: V. Results from the testing of 311 chemicals , 1992, Environmental and molecular mutagenesis.

[25]  E. Zeiger,et al.  Salmonella mutagenicity tests: III. Results from the testing of 255 chemicals. , 1987, Environmental mutagenesis.

[26]  D. Brusick,et al.  The Salmonella typhimurium/mammalian microsomal assay. A report of the U.S. Environmental Protection Agency Gene-Tox Program. , 1986, Mutation research.

[27]  D. Sanderson,et al.  Computer Prediction of Possible Toxic Action from Chemical Structure; The DEREK System , 1991, Human & experimental toxicology.

[28]  B. Burlinson,et al.  Use of the Miniscreen assay to screen novel compounds for bacterial mutagenicity in the pharmaceutical industry. , 1996, Mutagenesis.

[29]  E. Zeiger,et al.  Handbook of Carcinogenic Potency and Genotoxicity Databases , 1996 .

[30]  J. K. Clark,et al.  Is Mannitol Metabolized?∗ , 1948, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[31]  D J Brusick,et al.  International Commission for Protection Against Environmental Mutagens and Carcinogens. A method for comparing and combining short-term genotoxicity test data: the basic system. , 1992, Mutation research.

[32]  S. De Flora,et al.  Modulation of the potency of promutagens and direct acting mutagens in bacteria by inhibitors of the multidrug resistance mechanism. , 1997, Mutagenesis.

[33]  O. Pelkonen,et al.  Inhibition of hepatic microsomal drug metabolism in rats by five calcium antagonists. , 1989, Pharmacology & toxicology.

[34]  T. Shimada,et al.  Genotoxic and mutagenic activation of aflatoxin B1 by constitutive forms of cytochrome P-450 in rat liver microsomes. , 1987, Toxicology and applied pharmacology.

[35]  Evaluation of the genotoxicity of process stream extracts from a coal gasification system. , 1984, Environmental mutagenesis.

[36]  E. Zeiger,et al.  Salmonella mutagenicity tests: IV. Results from the testing of 300 chemicals , 1988, Environmental and molecular mutagenesis.

[37]  M D Waters,et al.  The Genetic Activity Profile database. , 1991, Environmental health perspectives.

[38]  R. Snyder,et al.  Comparison of the results of a modified miniscreen and the standard bacterial reverse mutation assays , 2000, Environmental and molecular mutagenesis.

[39]  E. Gocke,et al.  Mutagenicity study of Remsen-Fahlberg saccharin and contaminants. , 1980, Toxicology letters.

[40]  Mutagenicity and toxicity of aflatoxin precursors. , 1982, Environmental mutagenesis.

[41]  E. S. West,et al.  On the metabolism of scrbitol and mannitol. , 1939 .

[42]  W. Seinen,et al.  BACTERIAL MUTAGENICITY OF DICYCLOPENTA-FUSED PYRENE CONGENERS IN FVT-PYROLYSATES: PARTIAL COMBUSTION EXHAUST MIMICS , 2004 .

[43]  K. Hamada,et al.  The Effect of Diltiazem and Verapamil on Hepatic Microsomal Drug Metabolizing Enzymes in Rat , 1991 .

[44]  E. Zeiger,et al.  Salmonella mutagenicity tests: II. Results from the testing of 270 chemicals. , 1986, Environmental mutagenesis.

[45]  Hannu Komulainen,et al.  Bacterial and mammalian‐cell genotoxicity of mixtures of chlorohydroxyfuranones, by‐products of water chlorination , 2004, Environmental and molecular mutagenesis.

[46]  J. Berridge Impurities in drug substances and drug products: new approaches to quantification and qualification. , 1995, Journal of pharmaceutical and biomedical analysis.

[47]  Nigel Greene,et al.  The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development. , 2006, Regulatory toxicology and pharmacology : RTP.

[48]  Spiral Salmonella assay: Validation against the standard pour‐plate assay , 1996, Environmental and molecular mutagenesis.

[49]  P. Lohman Qualitative and quantitative procedures for health risk assessment. , 1999, Mutation research.

[50]  D. Jones,et al.  Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. , 1999, The Journal of pharmacology and experimental therapeutics.

[51]  Sac-fry Stages,et al.  OECD GUIDELINE FOR TESTING OF CHEMICALS , 2002 .

[52]  L. Wheeler,et al.  A comparison of aflatoxin B1-induced cytotoxicity, mutagenicity and prophage induction in Salmonella typhimurium mutagen tester strains TA1535, TA1538, TA98 and TA100. , 1981, Mutation research.